Calciphylaxis Market Report 2026

The calciphylaxis market size has grown strongly in recent years. It will grow from $3.54 billion in 2025 to $3.88 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to improved recognition of rare vascular disorders, advancements in diagnostic imaging methods, increased clinical awareness of calciphylaxis, availability of specialized wound care techniques, expansion of hospital-based treatment programs.

The calciphylaxis market size is expected to see strong growth in the next few years. It will grow to $5.55 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing research into targeted calcification therapies, rising adoption of personalized treatment protocols, expansion of multidisciplinary care models, growing investment in rare disease research, increasing use of advanced wound healing technologies. Major trends in the forecast period include increasing focus on early diagnosis of vascular calcification, rising use of advanced imaging techniques, growing integration of multimodal treatment approaches, expansion of specialized wound care protocols, enhanced emphasis on pain management strategies.

The increasing prevalence of chronic kidney disease (CKD) is anticipated to drive the growth of the calciphylaxis market in the coming years. Chronic kidney disease is a progressive condition in which the kidneys gradually lose their ability to filter waste products and excess fluids from the bloodstream, potentially resulting in kidney failure over time. The growing incidence of CKD is linked to factors such as an aging population, a rising burden of diabetes and hypertension, unhealthy lifestyle habits, and inadequate early diagnosis and management of kidney-related disorders. Calciphylaxis acts as a key marker of severe vascular complications associated with chronic kidney disease (CKD), underscoring the importance of early intervention and better management of mineral imbalances to reduce the risk of tissue necrosis and related morbidity. For example, in June 2023, Kidney Research UK, a UK-based charity focused on funding kidney disease research, reported that by 2033, the number of people affected by CKD stages 3-5 is projected to increase to approximately 3.9 million. Consequently, the rising incidence of chronic kidney disease (CKD) is contributing to the growth of the calciphylaxis market.

The rising prevalence of obesity is anticipated to drive the growth of the calciphylaxis market in the coming years. Obesity is a medical condition marked by excessive accumulation of body fat, which elevates the risk of several health problems, including cardiovascular disease, diabetes, and hypertension. The growing incidence of obesity is driven by factors such as inactive lifestyles, consumption of high-calorie diets, genetic susceptibility, and limited availability of nutritious food options. Obesity increases the risk of calciphylaxis through metabolic disturbances, persistent inflammation, and vascular calcification, which aggravate calcium-phosphate imbalance and endothelial injury, particularly among individuals with chronic kidney disease. For example, in May 2025, data from the Office for Health Improvement and Disparities (OHID), a UK government body, reported that during 2023-2024, approximately 64.5% of adults aged 18 and above in England were estimated to be overweight or living with obesity, representing a slight increase from 64% in 2022-2023. Consequently, the growing prevalence of obesity is contributing to the expansion of the calciphylaxis market.

Leading companies in the calciphylaxis market are concentrating on the development of advanced treatment options, including enzyme replacement therapies, to enhance clinical outcomes and lessen disease severity. Enzyme replacement therapy (ERT) is a therapeutic approach that involves supplementing the body with an enzyme that is absent or insufficient. It is most commonly applied in the management of rare genetic conditions in which the body is unable to produce a specific enzyme required for normal cellular function. For example, in October 2024, Inozyme Pharma Inc., a US-based biopharmaceutical company, reported positive interim findings from its Phase 1 SEAPORT 1 clinical trial evaluating INZ-701 in patients with end-stage kidney disease (ESKD). The interim results demonstrate the potential of INZ-701 to restore essential enzyme activity that helps prevent abnormal mineralization, a major contributor to severe rare disorders. The therapy is developed as an enzyme replacement treatment targeting ENPP1 and ABCC6 deficiencies, which are linked to pathological calcium accumulation in blood vessels and tissues.

Major companies operating in the calciphylaxis market are Hope Pharmaceuticals Ltd, Sanofi S.A., Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca plc, Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Johnson And Johnson, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Ipsen SA, Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, Horizon Therapeutics plc.

North America was the largest region in the calciphylaxis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calciphylaxis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calciphylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the calciphylaxis market by increasing costs of imported diagnostic imaging equipment, wound care materials, pharmaceuticals, and specialized medical devices used in disease management. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on advanced imported technologies, while Asia-Pacific faces higher costs for expanding diagnostic capabilities. These tariffs are increasing treatment expenses and limiting access in some regions. However, they are also encouraging domestic production of medical supplies, regional research collaborations, and localized development of treatment solutions for rare vascular disorders.

The calciphylaxis market research report is one of a series of new reports that provides calciphylaxis market statistics, including calciphylaxis industry global market size, regional shares, competitors with a calciphylaxis market share, detailed calciphylaxis market segments, market trends and opportunities, and any further data you may need to thrive in the calciphylaxis industry. This calciphylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Calciphylaxis is a rare and life-threatening disorder marked by the calcification of small blood vessels, resulting in skin tissue death and intense pain. It is studied to better understand vascular calcification conditions and to develop targeted therapies aimed at enhancing wound healing and managing pain in affected individuals.

The primary types of calciphylaxis include non-uremic calciphylaxis, ulcers and wounds, and wound debridement. Non-uremic calciphylaxis is an uncommon variant that develops in patients without chronic kidney disease or dialysis dependence. It involves abnormal calcium accumulation in small blood vessels, causing tissue injury, severe pain, and necrosis. Management approaches include pharmacological treatment and hyperbaric oxygen therapy, while diagnosis relies on deep skin biopsies, laboratory testing, and imaging techniques. Major end users comprise hospitals, clinics, home care settings, and ambulatory care centers.

The calciphylaxis market consists of revenues earned by entities by providing services such as chronic care management, nutritional counselling and patient management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The calciphylaxis market also includes sales of dialysis equipment, phosphate binders, vitamin k2 supplements, and wound care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.